Prostate‐specific antigen testing by income, age, and region: a nationwide population‐based study
BJU International · 18.11.2026
DOI: 10.1111/bju.70549 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 18.11.2026. Verfasst von Armando Galdieri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Urology Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Swedish Research Council, The Swedish Cancer Society, Forskningsrådet om Hälsa, Arbetsliv och Välfärd.
Abstract (Originalsprache)
Objective
To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in Sweden without a prior diagnosis of prostate cancer between 2000 and 2023. The proportion of men that underwent at least one PSA test between 1 January and 31 December was estimated each year overall and stratified by income (bottom 25%, middle 50%, top 25%), age, and region of residence.
Results
The PSA testing was higher in the top income group across all ages. In 2019, prior to the coronavirus disease 2019 pandemic, overall PSA testing was 17% and ranged from 13% in the bottom income group to 20% in the top. Overall, PSA testing and income‐related differences in PSA testing varied substantially between regions. In 2019, PSA testing varied between 12% and 20% between regions and difference in PSA testing between men with lowest and highest income ranged from 3.6% to 10% across regions. In regions with high PSA testing the difference in testing according to income was not smaller than in regions with little testing. PSA testing was higher among men aged 80–90 years (22%) than among men aged 50–59 years (13%).
Conclusions
Men in the highest income group underwent PSA testing more frequently, and many older men were tested despite guideline recommendations to the contrary. This pattern of opportunistic, unstructured testing not only leads to inequity but also high rates of testing in men at greatest risk of harm and least likely to benefit. These findings underscore the need for organised prostate cancer testing.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Urology Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
- Vita-Salute San Raffaele University, Milan, Italy.
- School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Surgery and Urology, Unit of Urology, Uppsala University Hospital, Uppsala, Sweden.
ORCID-Profile: Armando Galdieri, Rolf Gedeborg, Eugenio Ventimiglia, Ulf Strömberg, Ola Bratt, Marcus Westerberg
Förderung
- The Swedish Research Council
- The Swedish Cancer Society
- Forskningsrådet om Hälsa, Arbetsliv och Välfärd
- the Swedish Prostate Cancer Association (Prostatacancerförbundet)
- Vetenskapsrådet
- Cancerfonden
Zitieren
APA
Galdieri, A., Gedeborg, R., Garmo, H., Ventimiglia, E., Strömberg, U., Bratt, O., Stattin, P., & Westerberg, M. (2026). Prostate‐specific antigen testing by income, age, and region: a nationwide population‐based study. BJU International. https://doi.org/10.1111/bju.70549
Vancouver
Galdieri A, Gedeborg R, Garmo H, Ventimiglia E, Strömberg U, Bratt O, et al. Prostate‐specific antigen testing by income, age, and region: a nationwide population‐based study. BJU International. 2026. doi:10.1111/bju.70549
BibTeX
@article{Galdieri2026,
author = {Galdieri, Armando and Gedeborg, Rolf and Garmo, Hans and Ventimiglia, Eugenio and Strömberg, Ulf and Bratt, Ola and Stattin, Pär and Westerberg, Marcus},
title = {Prostate‐specific antigen testing by income, age, and region: a nationwide population‐based study},
journal = {BJU International},
year = {2026},
doi = {10.1111/bju.70549}
}
EUVIMED